Stock AnalizCOMPASS Pathways plc CMPS
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
COMPASS Pathways plc (CMPS) is a healthcare company listed in the US with a market value of about $1.3B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -47%.
Score: 0.4 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$288M | -$155M | -$118M | -$92M | -$72M | -$60M | -$20M |
| Free cash flow | — | -$119M | -$97M | -$106M | -$68M | -$42M | -$18M |
| EPS (diluted) | $-2.03 | $-1.09 | $-0.84 | $-0.65 | $-0.51 | $-0.43 | $-0.14 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | — | -75.3% | -41.8% | -47.6% | -22.8% | -20.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $23.31, 159% above the current price; targets range from $10.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $-1.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does COMPASS Pathways pay a dividend?
Not currently.
Is COMPASS Pathways a good stock to buy?
We do not give buy or sell advice. COMPASS Pathways scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.